Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

21 May 2022: Clinical Research

Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation

Yifan Li AE , Diwen Zhu BCD , Weixin Ren AE* , Junpeng Gu BCD , Weizheng Ji BCD , Haixiao Zhang BCD , Yingjun Bao BCD , Gengfei Cao BCD , Asihaer Hasimu BCD

DOI: 10.12659/MSM.936246

Med Sci Monit 2022; 28:e936246

Table 1 Comparison of low-risk and high-risk groups receiving combined TACE and RFA therapy.

VariablesTotal (n=142)Low-risk (n=86)High-risk (n=56)StatisticsP
Sex, n (%)χ=9.0200.003
 Female31 (21.83)26 (30.23)5 (8.93)
 Male111 (78.17)60 (69.77)51 (91.07)
Age, Mean±SD59.90±10.5761.38±10.1957.63±10.83t=2.090.038
Tumor location, n (%)χ=0.9850.611
 Right liver93 (65.49)59 (68.60)34 (60.71)
 Left liver17 (11.97)9 (10.47)8 (14.29)
 Bilateral liver32 (22.54)18 (20.93)14 (25.00)
Tumor number, n (%)χ=6.2710.043
 One98 (69.01)61 (70.93)37 (66.07)
 Two21 (14.79)8 (9.30)13 (23.21)
 Three or more23 (16.20)17 (19.77)6 (10.71)
Tumor size, n (%)χ=1.4870.685
 ≤3 cm9 (6.34)7 (8.14)2 (3.57)
 3–5 cm54 (38.03)33 (38.37)21 (37.50)
 5–10 cm76 (53.52)44 (51.16)32 (57.14)
 >10 cm3 (2.11)2 (2.33)1 (1.79)
PVTT, n (%)χ=0.0240.876
 No125 (88.03)76 (88.37)49 (87.50)
 Yes17 (11.97)10 (11.63)7 (12.50)
Hepatitis, n (%)χ=3.5710.059
 No29 (20.42)22 (25.58)7 (12.50)
 Yes113 (79.58)64 (74.42)49 (87.50)
Number of TACEs in the first treatment cycle, M (Q, Q)1.00 (1.00,1.00)1.00 (1.00,1.00)1.00 (1.00,1.00)Z=−0.0120.990
Number of RFAs in the first treatment cycle, M (Q, Q)1.00 (1.00,1.00)1.00 (1.00,2.00)1.00 (1.00,1.00)Z=−4.738
AFP, ng/ml, M (Q, Q)14.35 (4.40, 235.00)12.60 (3.60, 170.30)17.85 (4.90, 277.40)Z=1.0170.309
Tbil, μmol/L, M (Q, Q)16.50 (10.90, 20.80)16.05 (10.90, 22.06)16.85 (11.70, 20.27)Z=0.0540.957
Albumin, g/L, Mean±SD38.55±6.0738.55±5.8738.55±6.42t=0.000.998
ALT, U/L, M (Q, Q)25.36 (18.20, 39.69)22.69 (15.40, 35.04)37.25 (19.65, 51.22)Z=3.465
AST, U/L, M (Q, Q)30.60 (22.85, 42.50)27.70 (22.50, 40.50)33.20 (23.60, 44.10)Z=2.0390.041
LDH, U/L, Mean±SD189.82±41.75189.73±41.59189.96±42.37t=−0.030.975
ALP, U/L, M (Q, Q)91.50 (70.00, 126.00)87.50 (70.00, 116.70)100.95 (70.50, 139.95)Z=1.0620.288
Child-Pugh, n (%)χ=0.3670.545
 A127 (89.44)78 (90.70)49 (87.50)
 B15 (10.56)8 (9.30)7 (12.50)
BCLC, n (%)χ=0.1830.913
 A69 (48.59)43 (50.00)26 (46.43)
 B58 (40.85)34 (39.53)24 (42.86)
 C15 (10.56)9 (10.47)6 (10.71)
CNLC, n (%)χ=2.9670.563
 Ia54 (38.03)35 (40.70)19 (33.93)
 Ib30 (21.13)18 (20.93)12 (21.43)
 IIa22 (15.49)10 (11.63)12 (21.43)
 IIb16 (11.27)11 (12.79)5 (8.93)
 IIIa20 (14.08)12 (13.95)8 (14.29)
The outcome, n (%)χ=48.964
 No progression or survival86 (60.56)72 (83.72)14 (25.00)
 Progression or death56 (39.44)14 (16.28)42 (75.00)
PVTT – portal vein tumor thrombus; TACE – transarterial chemoembolization; RFA – radiofrequency ablation; AFP – alpha-fetoprotein; Tbil – total bilirubin; ALT – alanine transaminase; AST – aspartate transaminase; LDH – lactic dehydrogenase; ALP – alkaline phosphatase; BCLC – Barcelona Clinic Liver Cancer; CNLC – China liver cancer staging.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750